Featured Research

from universities, journals, and other organizations

A step closer to finding treatment for dengue fever

Date:
July 31, 2014
Source:
SingHealth
Summary:
Researchers are now a step closer to finding a treatment for dengue fever. In the CELADEN study completed last year, medical researchers found that Celgosivir is generally safe and well-tolerated by patients affected with the dengue virus. The discovery has moved to the next phase of trial to evaluate the efficacy and safety of an alternate dosing regimen as well as combination drug treatments.

There have been several news reports that the world's first dengue vaccine will be available next year. However, the latest clinical trials show that the vaccine only provides a protection of around 50 per cent for DENV-2 and DENV-1, which are commonly found in Singapore.

DENV-1 accounts for 90 per cent of infections locally as a large population lacks the immunity against this particular dengue virus serotype. Until a vaccine that can offer higher protection becomes available, it is crucial to find a suitable treatment for dengue fever, as there is presently none available world-wide.

The good news is that a team of Singapore General Hospital (SGH) and Duke-NUS Graduate Medical School (Duke-NUS) researchers are now a step closer to finding a treatment for dengue fever. In the CELADEN study completed last year, the team found that Celgosivir, a medicine derived from a naturally occurring compound found in the seeds of the Moreton Bay Chestnut tree, is generally safe and well-tolerated by patients affected with the dengue virus.

Participants recruited for the study were admitted to SGH for five days, during which time they received either the placebo or Celgosivir. They continued to be followed up on days 7, 10 and 15 at the outpatient clinics where clinical histories and blood were taken. A physical examination of the patient was also done during these sessions.

"We found that the drug regimen in our CELADEN study was well-tolerated. And because dengue virus is cleared from the blood within three to five days and fever subsides in the same period, a regimen with more frequent dosing will be tested in the next phase of our trial to see its therapeutic effect," said Dr Jenny Low, Senior Consultant, Department of Infectious Diseases, SGH, and Principal Investigator of the study.

"Prior work conducted at Duke-NUS has demonstrated that dose regimen is an important factor in mediating the antiviral effects of Celgosivir," said Professor Subhash Vasudevan, Emerging Infectious Diseases Program at Duke-NUS.

The findings of the study were published in Lancet Infectious Diseases on 28 May 2014.

Moving to the next phase of the study, SingHealth and Duke-NUS have signed an exclusive licensing agreement with 60 Degrees Pharmaceuticals to evaluate the efficacy and safety of an alternate dosing regimen as well as combination drug treatments in dengue patients. The NUS Industry Liaison Office, which is part of NUS Enterprise, took the lead in coordinating and facilitating this multi-party collaboration and the license negotiation.

"Other viral diseases such as hepatitis C and HIV required combination regimens to demonstrate clinical benefit. This may also be the case for dengue. To that end, 60P has also entered into a collaboration agreement with NUS earlier in March 2014 to investigate the utility of drug combinations in animal models. This agreement builds on prior collaborations between the parties to evaluate the antiviral effects of other approved drugs," said Mr Geoff Dow, CEO, 60P.

Dengue fever is an acute febrile illness transmitted by mosquitoes, which affects half the world's population. There are 96 million symptomatic infections, 500,0000 hospitalisations and 25,000 deaths per year attributed to the disease. The economic burden is $12 billion. In Singapore, as elsewhere, the incidence of the disease has continued to increase despite aggressive control measures.


Story Source:

The above story is based on materials provided by SingHealth. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jenny G Low, Cynthia Sung, Limin Wijaya, Yuan Wei, Abhay P S Rathore, Satoru Watanabe, Boon Hian Tan, Liying Toh, Lian Tee Chua, Yan'an Hou, Angelia Chow, Shiqin Howe, Wing Ki Chan, Kah Hin Tan, Jasmine S Chung, Benjamin P Cherng, David C Lye, Paul A Tambayah, Lee Ching Ng, John Connolly, Martin L Hibberd, Yee Sin Leo, Yin Bun Cheung, Eng Eong Ooi, Subhash G Vasudevan. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. The Lancet Infectious Diseases, 2014; 14 (8): 706 DOI: 10.1016/S1473-3099(14)70730-3

Cite This Page:

SingHealth. "A step closer to finding treatment for dengue fever." ScienceDaily. ScienceDaily, 31 July 2014. <www.sciencedaily.com/releases/2014/07/140731095324.htm>.
SingHealth. (2014, July 31). A step closer to finding treatment for dengue fever. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2014/07/140731095324.htm
SingHealth. "A step closer to finding treatment for dengue fever." ScienceDaily. www.sciencedaily.com/releases/2014/07/140731095324.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Costs Keep Mounting

Ebola Costs Keep Mounting

Reuters - Business Video Online (Sep. 23, 2014) The WHO has warned up to 20,000 people could be infected with Ebola over the next few weeks. As Sonia Legg reports, the implications for the West African countries suffering from the disease are huge. Video provided by Reuters
Powered by NewsLook.com
Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins